Some GLP-1 drugs such as Ozempic are intended for clinical use in treating people living with diabetes. Over the past few years, however, GLP-1s have been prescribed more frequently for weight loss only. This has vastly increased patterns of off-label use, caused shortages for patients who rely on these drugs for diabetes management, and driven industry-wide cost trend increases.
To ensure availability and align our practices with other carriers, we are making a change to our GLP-1 coverage policies.
What you need to know:
-
As of May 1, 2024, members with an active prior authorization, managing Type II diabetes, will continue to have access to GLP-1 medications.
-
As of May 1, 2024, new requests to use GLP-1 drugs for prediabetes are not eligible for coverage.
-
What is changing as of September 1, 2024: Members with prediabetes who are already receiving GLP-1s will continue to have access until their prior authorization expires. After it expires, renewals will not be approved.
Impacted members will receive a 60-day notice. Members can continue to take advantage of our many prediabetes and weight loss resources. Dietitian visits are covered under most plans, and many of our members have access to prediabetes education and resources through Sharecare. We also have new weight loss programs rolling out in the coming months, and we will share more details soon.
Price Edge Launch Date Delayed for ACA Plans:
In previous communications, we announced that Price Edge would be available to Small Group ACA plans starting 7/1/2024. The launch date has been delayed.
When we have a new launch date, we will share that with you. We apologize for any confusion.
|